SCHEMBL2385291

SCHEMBL2385291

CCCCNc1cc(COc2nsnc2N2CCNCC2)ccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 7/20 0.58
FLT3 P36888 1/20 0.43
TYRO3 Q06418 1/20 0.43
MERTK Q12866 1/20 0.43
GAS6 Q14393 1/20 0.43
HSD17B10 Q99714 3/20 0.42
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTR2C P28335 3/20 0.35
PRKD1 Q15139 1/20 0.35
PRKD2 Q9BZL6 1/20 0.35
ACHE P22303 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383246 0.94 HRH4 (0.49) HRH4FLT3TYRO3MERTKGAS6
SCHEMBL2385794 0.90 HSD17B10 (0.45) HRH4HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL2383055 0.86 ALDH1A1 (0.46) HRH4HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL2384253 0.78 ALDH1A1 (0.49) HSD17B10ALDH1A1ALOX15TSHRMAPK1
SCHEMBL2386418 0.77 TRPV1 (0.41) HSD17B10MAPK1LMNASMN1; SMN2HTT
SCHEMBL2382669 0.77 ALDH1A1 (0.57) HRH4HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL12251227 0.75 ALDH1A1 (0.53) HRH4HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL846291 0.74 HRH4 (1.00) HRH4FLT3TYRO3MERTKGAS6
Hydrochloric Acid SCHEMBL2383364 0.74 ALDH1A1 (0.52) HRH4HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL2383522 0.72 TRPV1 (0.42) LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR HRH4 2917/4885FLT3 270/4885TYRO3 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.